
    
      The primary objective is to assess the treatment strategy of using PRO 140 SC as long-acting,
      single-agent maintenance therapy for the chronic suppression of CCR5-tropic HIV-1 infection.
      In addition, the prognostic factors of therapeutic success of PRO 140 monotherapy will be
      evaluated.

      The secondary objective of the trial is to assess the clinical efficacy, safety and
      tolerability parameters following substitution of combination antiretroviral therapy with
      weekly PRO 140 monotherapy.
    
  